News & Press Releases

Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.

Member Jacob Hupart was quoted in a Responsible Investor article about a lawsuit challenging the SEC’s pullback from its long standing “no action” review process for shareholder proposals. In the article, Jacob addresses the legal hurdles facing the plaintiffs as they seek to frame the SEC’s policy shift as actionable under the Administrative Procedure Act.

Member Jen Rubin was quoted in a Lexology Pro article examining why US legal teams should reassess their use of non solicitation agreements amid evolving regulatory scrutiny and state laws. Her comments address how courts and regulators increasingly distinguish non solicitation provisions from non competes and the risks employers face when non solicits are drafted too broadly.

Mintz represented Swarmer, Inc (Nasdaq: SWMR), a defense technology company specializing in drone autonomy software, in its initial public offering on the Nasdaq Capital Market. 

Daniel DeWolf, Co-chair of Mintz’s Venture Capital & Emerging Companies Practice, was featured as a guest on the ABA podcast To the Extent That…. The episode explores how venture capital firms use warehouse investing as part of their fund formation strategy and the main legal, regulatory, and tax considerations involved.

Mintz represented Sixth Street in connection with a $1.3 billion financing – alongside co-investor Blackstone Credit & Insurance – in support of the combination of Paratek Pharmaceuticals (Paratek) and Radius Health (Radius), creating a scaled, multi‑product specialty pharmaceutical company backed by B‑FLEXION Life Sciences.